Death complex linked to Alzheimer's may be blocked by experimental drug

Researchers report a protein interaction they call a 'death complex' appears at higher levels in an Alzheimer's mouse model, and the experimental compound FP802 blocked that interaction and reduced nerve-cell damage; further drug development and clinical testing are required.

Researchers at Heidelberg University and collaborators report identifying a protein interaction described as a "death complex" that can damage nerve cells and appears more often in a mouse model of Alzheimer's disease. The work focused on an interaction between NMDA receptors and the TRPM4 ion channel occurring outside synapses. The team tested an experimental compound called FP802, which they report disrupted this interaction in mice and limited several cellular changes tied to the disease. The study is presented as an alternative approach to therapies that focus directly on amyloid. Key findings: - The study used a mouse model of Alzheimer's and found higher levels of an NMDA receptor–TRPM4 interaction that researchers describe as a "death complex." - The experimental compound FP802 was reported to block this interaction, slow disease progression in the mice, and help preserve learning and memory in the experiments. - FP802 treatment was also reported to reduce amyloid beta deposits and to limit synapse loss and mitochondrial damage in the studied animals. - The research team emphasized that comprehensive pharmacological development, toxicological experiments and clinical studies will be needed before any application in humans. Summary: The finding identifies a downstream cellular mechanism that may contribute to nerve-cell death in Alzheimer's and offers a different target than therapies focused on amyloid. In the reported mouse experiments, FP802 disrupted the NMDA/TRPM4 interaction and reduced several cellular and cognitive signs of disease. Researchers say further drug development, toxicology testing and clinical trials are required before human use can be considered.